AstraZeneca Phase 3 Trial for Rare Vasculitis Treatment Meets Primary Endpoint
11 Setembro 2023 - 02:48PM
Dow Jones News
By Ben Glickman
AstraZeneca said Monday that a Phase 3 trial of its treatment
for eosinophilic granulomatosis with polyangiitis, a rare form of
vasculitis, met its primary endpoint.
The pharmaceutical company said that its trial of Fasenra also
demonstrated non-inferior rates of remission compared to
mepolizumab, the only approved treatment for EGPA.
The company said that EGPA is a rare disease caused by
inflammation of small to medium-sized blood vessels. About half of
patients with EGPA develop a form of asthma, and the disease can
cause damage to organs.
Fasenra received orphan drug designation from the U.S. Food and
Drug Administration as a treatment for EGPA. The company said that
the treatments safety and tolerability profile in the trial was
consistent with Fasenra's profile, and that the full results of the
trial would be presented at an upcoming medical meeting.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
September 11, 2023 13:33 ET (17:33 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Gráfico Histórico do Ativo
De Nov 2023 até Dez 2023
Astrazeneca (LSE:AZN)
Gráfico Histórico do Ativo
De Dez 2022 até Dez 2023
